What changed in Idexx Laboratories Inc /De's latest annual report
In the year ended 31 Dec 2025, Idexx Laboratories Inc /De's revenue rose 10.4% to USD 4.30bn, from USD 3.90bn; net income rose 19.3% to USD 1.06bn, from USD 887.87m; cash and cash equivalents fell 37.5% to USD 180.07m, from USD 288.27m.
Year ended 31 Dec 2025. Source: 10-K filed 20 Feb 2026, read it on SEC EDGAR.
USD 3.90bn to USD 4.30bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 3.90bn | 4.30bn | Up 10.4% |
| Net income | 887.87m | 1.06bn | Up 19.3% |
| Total assets | 3.29bn | 3.35bn | Up 1.7% |
| Total liabilities | 1.70bn | 1.75bn | Up 2.8% |
| Long-term debt | 449.79m | 374.84m | Down 16.7% |
| Cash and cash equivalents | 288.27m | 180.07m | Down 37.5% |
| Shareholders' equity | 1.60bn | 1.61bn | Up 0.6% |
Questions people ask
Did Idexx Laboratories Inc /De's revenue grow last year?
Revenue grew 10.4%, from USD 3.90bn to USD 4.30bn in the year ended 31 Dec 2025.
Is Idexx Laboratories Inc /De profitable?
Yes. Net income was USD 1.06bn in the year ended 31 Dec 2025. The year before: USD 887.87m.
How much cash and debt does Idexx Laboratories Inc /De have?
At its latest year end (31 Dec 2025), Idexx Laboratories Inc /De reported cash and cash equivalents of USD 180.07m and long-term debt of USD 374.84m.
Where do these numbers come from?
From Idexx Laboratories Inc /De's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Idexx Laboratories Inc /De?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demo